AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
November 11, 2024 at 15:19 PM EST
AbbVie reports disappointing mid-stage data for its schizophrenia drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|